NCT07413939 2026-03-10
BREnnA
Hoffmann-La Roche
Phase 2/3 Not yet recruiting
Clinical Trials
13 trialsNCT07377643 2026-02-25
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 3 Recruiting
NCT03571633 2025-11-26
BREASTIMMU02
Centre Leon Berard
Phase 2 Active not recruiting
NCT03738553 2025-10-29
Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy
University of Washington
Active not recruiting
NCT04419181 2025-10-14
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
University of Rochester
Phase 2 Withdrawn
NCT07043725 2025-09-23
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Recruiting
NCT07179939 2025-09-18
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Fudan University
Phase 2 Not yet recruiting
NCT03588091 2025-08-22
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT07116824 2025-08-12
HB1801 Combined Treatment of HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT07115095 2025-08-11
Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer
Shaanxi Provincial Cancer Hospital
Phase NA Completed
NCT06992882 2025-07-18
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)
Fudan University
Phase 3 Recruiting
NCT04220203 2025-06-26
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Seagen Inc.
Approved for marketing
NCT05955170 2025-03-27
TUC-TOC
Institut Curie
Phase 2 Recruiting